MeadowBrook Investment Advisors LLC Makes New Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

MeadowBrook Investment Advisors LLC bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 3,055 shares of the medical equipment provider’s stock, valued at approximately $189,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of LNTH. M&T Bank Corp purchased a new position in Lantheus during the fourth quarter worth about $320,000. First Horizon Advisors Inc. lifted its stake in Lantheus by 103.9% in the 4th quarter. First Horizon Advisors Inc. now owns 932 shares of the medical equipment provider’s stock worth $58,000 after purchasing an additional 475 shares in the last quarter. Retirement Systems of Alabama boosted its holdings in Lantheus by 0.4% in the 4th quarter. Retirement Systems of Alabama now owns 85,779 shares of the medical equipment provider’s stock valued at $5,318,000 after purchasing an additional 336 shares during the period. Sector Gamma AS grew its position in shares of Lantheus by 2.7% during the 4th quarter. Sector Gamma AS now owns 52,316 shares of the medical equipment provider’s stock valued at $3,244,000 after purchasing an additional 1,354 shares in the last quarter. Finally, Stanley Laman Group Ltd. bought a new position in Lantheus in the 4th quarter worth about $3,683,000. Institutional investors own 99.06% of the company’s stock.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares in the company, valued at approximately $16,434,804.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, major shareholder Lantheus Alpha Therapy, Llc bought 60,431,039 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were bought at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the purchase, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the sale, the director now directly owns 251,643 shares of the company’s stock, valued at $16,434,804.33. The disclosure for this sale can be found here. Insiders sold 94,545 shares of company stock valued at $6,169,936 over the last 90 days. Company insiders own 2.10% of the company’s stock.

Lantheus Stock Performance

NASDAQ LNTH traded down $0.02 during trading hours on Monday, hitting $75.51. The company’s stock had a trading volume of 1,231,847 shares, compared to its average volume of 1,081,704. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 4.55. The company has a market cap of $5.23 billion, a P/E ratio of 11.53 and a beta of 0.52. The company’s 50 day simple moving average is $62.67 and its two-hundred day simple moving average is $62.71. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $100.85.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.26. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The company had revenue of $354.00 million for the quarter, compared to the consensus estimate of $350.44 million. As a group, sell-side analysts expect that Lantheus Holdings, Inc. will post 5.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on LNTH shares. Truist Financial lifted their target price on shares of Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research report on Friday. JMP Securities reiterated a “market outperform” rating and issued a $100.00 target price on shares of Lantheus in a research report on Friday, February 23rd. B. Riley increased their target price on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday. Finally, Mizuho lifted their target price on shares of Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $99.17.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.